Suven Pharmaceuticals Limited (NSE:SUVENPHAR) — Stock Price
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) is currently trading at Rs1063.80 INR, up 0.00% today. Over the past 52 weeks, shares have ranged between Rs1063.80 and Rs1063.80. This page tracks Suven Pharmaceuticals Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Suven Pharmaceuticals Limited (SUVENPHAR) total market value.
Suven Pharmaceuticals Limited (SUVENPHAR) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Suven Pharmaceuticals Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daily price history is not currently available for Suven Pharmaceuticals Limited.
Suven Pharmaceuticals Limited Income Statement — Revenue, Profit & Earnings by Year
Suven Pharmaceuticals Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs11.98 Billion | Rs10.51 Billion | Rs13.40 Billion | Rs12.90 Billion | Rs9.80 Billion |
| Cost of Revenue | Rs3.05 Billion | Rs4.49 Billion | Rs5.85 Billion | Rs5.55 Billion | Rs4.20 Billion |
| Gross Profit | Rs8.92 Billion | Rs6.03 Billion | Rs7.55 Billion | Rs7.35 Billion | Rs5.60 Billion |
| Research & Development | — | Rs111.20 Million | Rs85.86 Million | Rs103.55 Million | Rs110.58 Million |
| SG&A | — | Rs1.37 Billion | Rs189.32 Million | Rs170.64 Million | Rs160.52 Million |
| Total Operating Expenses | Rs5.95 Billion | Rs1.40 Billion | Rs2.36 Billion | Rs1.92 Billion | Rs1.48 Billion |
| Operating Income | Rs2.98 Billion | Rs4.61 Billion | Rs5.19 Billion | Rs5.42 Billion | Rs4.10 Billion |
| EBITDA | Rs4.34 Billion | Rs4.68 Billion | Rs6.20 Billion | Rs6.74 Billion | Rs4.57 Billion |
| EBIT | Rs3.56 Billion | Rs4.13 Billion | Rs5.73 Billion | Rs6.35 Billion | Rs4.25 Billion |
| Interest Expense | Rs123.50 Million | Rs74.51 Million | Rs128.11 Million | Rs84.31 Million | Rs114.06 Million |
| Income Before Tax | Rs3.44 Billion | Rs4.06 Billion | Rs5.60 Billion | Rs6.68 Billion | Rs4.68 Billion |
| Income Tax Expense | Rs791.50 Million | Rs1.05 Billion | Rs1.48 Billion | Rs2.14 Billion | Rs1.05 Billion |
| Net Income | Rs2.65 Billion | Rs3.00 Billion | Rs4.11 Billion | Rs4.54 Billion | Rs3.62 Billion |
Suven Pharmaceuticals Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Suven Pharmaceuticals Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs30.32 Billion | Rs22.54 Billion | Rs19.66 Billion | Rs18.30 Billion | Rs14.74 Billion |
| Total Current Assets | Rs8.89 Billion | Rs12.63 Billion | Rs10.11 Billion | Rs11.28 Billion | Rs5.65 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs2.05 Billion | Rs7.74 Billion | Rs4.22 Billion | Rs4.81 Billion | Rs1.81 Billion |
| Net Receivables | Rs2.85 Billion | Rs1.34 Billion | Rs1.11 Billion | Rs2.36 Billion | Rs1.02 Billion |
| Inventory | Rs1.67 Billion | Rs2.31 Billion | Rs3.13 Billion | Rs2.83 Billion | Rs2.01 Billion |
| Property, Plant & Equipment | — | — | — | Rs5.62 Billion | Rs5.35 Billion |
| Goodwill | Rs6.55 Billion | Rs602.58 Million | Rs602.58 Million | — | — |
| Total Liabilities | Rs11.91 Billion | Rs2.03 Billion | Rs2.31 Billion | Rs3.02 Billion | Rs2.94 Billion |
| Total Current Liabilities | Rs3.65 Billion | Rs1.07 Billion | Rs1.59 Billion | Rs2.10 Billion | Rs2.20 Billion |
| Long-term Debt | Rs62.40 Million | Rs0.00 | Rs45.64 Million | Rs284.40 Million | Rs355.91 Million |
| Net Debt | Rs1.94 Billion | Rs177.65 Million | Rs55.38 Million | Rs525.63 Million | Rs1.36 Billion |
| Total Stockholder Equity | Rs16.97 Billion | Rs20.51 Billion | Rs17.35 Billion | Rs15.27 Billion | Rs11.81 Billion |
| Retained Earnings | — | Rs17.65 Billion | Rs14.65 Billion | Rs12.73 Billion | Rs9.36 Billion |
Suven Pharmaceuticals Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Suven Pharmaceuticals Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs2.88 Billion | Rs3.58 Billion | Rs4.51 Billion | Rs3.30 Billion | Rs3.83 Billion |
| Capital Expenditures | Rs1.56 Billion | Rs517.87 Million | Rs2.86 Billion | Rs751.87 Million | Rs1.11 Billion |
| Free Cash Flow | Rs1.32 Billion | Rs3.07 Billion | Rs1.65 Billion | Rs2.55 Billion | Rs2.73 Billion |
| Investing Cash Flow | Rs-2.55 Billion | Rs-3.62 Billion | Rs-1.95 Billion | Rs-1.36 Billion | Rs-3.11 Billion |
| Financing Cash Flow | Rs33.20 Million | Rs-138.02 Million | Rs-2.36 Billion | Rs-1.56 Billion | Rs-765.53 Million |
| Dividends Paid | — | — | Rs2.04 Billion | Rs1.02 Billion | Rs254.56 Million |
| Stock-Based Compensation | Rs149.10 Million | Rs19.95 Million | — | — | — |
| Depreciation | Rs774.90 Million | Rs545.96 Million | Rs464.60 Million | Rs382.55 Million | Rs312.21 Million |
| Change in Cash | Rs383.70 Million | Rs-175.72 Million | Rs202.39 Million | Rs373.82 Million | Rs-45.13 Million |
Suven Pharmaceuticals Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Suven Pharmaceuticals Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 10, 2026 | — | — | — |
| Nov 10, 2025 | — | — | — |
| Aug 07, 2025 | — | — | — |
| Feb 03, 2025 | — | — | — |
| Nov 07, 2024 | — | — | — |
| May 09, 2022 | 3.60 | 5.00 | -28.00% |
| Nov 06, 2021 | 3.81 | 3.70 | +2.97% |
| Jun 08, 2021 | 3.27 | 3.80 | -13.95% |